Association between apolipoprotein E gene polymorphism and the risk of multiple sclerosis: A meta-analysis of 6977 subjects

Gene

Volumn 511, Issue 1, 2012, Pages 12-17

  Yin, Yan Wei ^a   Zhang, Yun Dong ^a   Wang, Jing Zhou ^a   Li, Bing Hu ^a   Yang, Qing Wu ^a   Fang, Chuan Qin ^a   Gao, Chang Yue ^a   Li, Jing Cheng ^a   Zhang, Li Li ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Apolipoprotein E; Meta analysis; Multiple sclerosis; Polymorphism

Indexed keywords

APOLIPOPROTEIN E2; APOLIPOPROTEIN E3; APOLIPOPROTEIN E4;

ALLELE; ARTICLE; DNA POLYMORPHISM; ETHNICITY; GENETIC ASSOCIATION; GENETIC RISK; GENOTYPE; HUMAN; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; SENSITIVITY ANALYSIS;

APOLIPOPROTEINS E; CASE-CONTROL STUDIES; GENE FREQUENCY; GENETIC ASSOCIATION STUDIES; HUMANS; MODELS, GENETIC; MULTIPLE SCLEROSIS; POLYMORPHISM, GENETIC; PUBLICATION BIAS; RISK FACTORS;

EID: 84867640621     PISSN: 03781119     EISSN: 18790038     Source Type: Journal    
DOI: 10.1016/j.gene.2012.09.010     Document Type: Article

References (37)

1. Al-Shammri S., Fatania H., Al-Radwan R., Akanji A.O. The relationship of APOE genetic polymorphism with susceptibility to multiple sclerosis and its clinical phenotypes in Kuwaiti Arab subjects. Clin. Chim. Acta 2005, 351:203-207.
2. Ballerini C., et al. Association of apolipoprotein E polymorphism to clinical heterogeneity of multiple sclerosis. Neurosci. Lett. 2000, 296:174-176.
3. Brück W. The pathology of multiple sclerosis is the result of focal inflammatory demyelination with axonal damage. J. Neurol. 2005, 252(Suppl. 5):v3-v9.
4. Bu G. Apolipoprotein E and its receptors in Alzheimer's disease: pathways, pathogenesis and therapy. Nat. Rev. Neurosci. 2009, 10:333-344.
5. Burwick R.M., et al. APOE epsilon variation in multiple sclerosis susceptibility and disease severity: some answers. Neurology 2006, 66:1373-1383.
6. Carlin C., Murray L., Graham D., Doyle D., Nicoll J. Involvement of apolipoprotein E in multiple sclerosis: absence of remyelination associated with possession of the APOE epsilon2 allele. J. Neuropathol. Exp. Neurol. 2000, 59:361-367.
7. Cocco E., et al. HLA-DR, DQ and APOE genotypes and gender influence in Sardinian primary progressive MS. Neurology 2005, 64:564-566.
8. Corder E.H., et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 1993, 261:921-923.
9. Ebers G.C., Sadovnick A.D., Risch N.J. A genetic basis for familial aggregation in multiple sclerosis. Canadian Collaborative Study Group. Nature 1995, 377:150-151.
10. Farrer L.A., et al. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. JAMA 1997, 278:1349-1356.
11. Ferri C., et al. APOE epsilon2-4 and -491 polymorphisms are not associated with MS. Neurology 1999, 53:888-889.
12. Gaillard O., et al. Apolipoprotein E and multiple sclerosis: a biochemical and genetic investigation. J. Neurol. Sci. 1998, 158:180-186.
13. Høgh P., et al. Apoliprotein E and multiple sclerosis: impact of the epsilon-4 allele on susceptibility, clinical type and progression rate. Mult. Scler. 2000, 6:226-230.
14. Huang Y. Apolipoprotein E and Alzheimer disease. Neurology 2006, 66(2 Suppl. 1):79-85.
15. Ignatius M.J., et al. Expression of apolipoprotein E during nerve degeneration and regeneration. Proc. Natl. Acad. Sci. U. S. A. 1986, 83:1125-1129.
16. Koch-Henriksen N., Hyllested K. Epidemiology of multiple sclerosis: incidence and prevalence rates in Denmark 1948-64 based on the Danish Multiple Sclerosis Registry. Acta Neurol. Scand. 1998, 78:369-380.
17. Koutsis G., et al. APOE genotypes in Greek multiple sclerosis patients: no effect on the MS Severity Score. J. Neurol. 2007, 254:394-395.
18. Lahiri D.K., Sambamurti K., Bennett D.A. Apolipoprotein gene and its interaction with the environmentally driven risk factors: molecular, genetic and epidemiological studies of Alzheimer's disease. Neurobiol. Aging 2004, 25:651-660.
19. Losonczi E., et al. APOE epsilon status in Hungarian patients with primary progressive multiple sclerosis. Swiss Med. Wkly. 2010, 140:w13119.
20. Mahley R.W. Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science 1988, 240:622-630.
21. Mehta P.D., Patrick B.A., Pirttila T., Coyle P.K., Aisen P.S. Detection of apolipoprotein E phenotype in unconcentrated cerebrospinal fluid. J. Clin. Lab. Anal. 2003, 17:18-21.
22. Moher D., Liberati A., Tetzlaff J., Altman D.G., PRISMA Group Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann. Intern. Med. 2009, 151:264-269.
23. Mustafina O.E., et al. Analysis of the association of allelic variants of apolypoprotein E and interleukin 1 beta genes with multiple sclerosis in ethnic Tatars. Genetika 2008, 44:407-413.
24. Niino M., Kikuchi S., Fukazawa T., Yabe I., Tashiro K. Polymorphisms of apolipoprotein E and Japanese patients with multiple sclerosis. Mult. Scler. 2003, 9:382-386.
25. Noonan C.W., Kathman S.J., White M.C. Prevalence estimates for MS in the United States and evidence of an increasing trend for women. Neurology 2002, 58:136-138.
26. Olesen J., et al. The economic cost of brain disorders in Europe. Eur. J. Neurol. 2012, 19:155-162.
27. Pinholt M., Frederiksen J.L., Andersen P.S., Christiansen M. Apo E in multiple sclerosis and optic neuritis: the apo E-epsilon4 allele is associated with progression of multiple sclerosis. Mult. Scler. 2005, 11:511-515.
28. Pirttilä T., Haanpää M., Mehta P.D., Lehtimäki T. Apolipoprotein E (APOE) phenotype and APOE concentrations in multiple sclerosis and acute herpes zoster. Acta Neurol. Scand. 2000, 102:94-98.
29. Ramsaransing G.S., Heersema D.J., De Keyser J. Serum uric acid, dehydroepiandrosterone sulphate, and apolipoprotein E genotype in benign vs. progressive multiple sclerosis. Eur. J. Neurol. 2005, 12:514-518.
30. Rubinsztein D.C. Apo E genotypes in multiple sclerosis, Parkinson's disease, schwannomas and late-onset Alzheimer's disease. Mol. Cell. Probes 1994, 8:519-525.
31. Savettieri G., et al. Apolipoprotein E genotype does not influence the progression of multiple sclerosis. J. Neurol. 2003, 250:1094-1098.
32. Strittmatter W.J., et al. Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc. Natl. Acad. Sci. U. S. A. 1993, 90:1977-1981.
33. Varadé J., et al. Replication study of 10 genes showing evidence for association with multiple sclerosis: validation of TMEM39A, IL12B and CLBL genes. Mult. Scler. 2011, 18:959-965.
34. Weatherby S.J., et al. Polymorphisms of apolipoprotein E; outcome and susceptibility in multiple sclerosis. Mult. Scler. 2000, 6:32-36.
35. Wells G.A., Shea B., O'Connell D. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses 2011, Ottawa Health Research Institute, www.ohri.ca/programs/clinical_epidemiology/oxford.asp (accessed Oct 20, 2011).
36. Zakrzewska-Pniewska B., et al. Association of apolipoprotein E and myeloperoxidase genotypes to clinical course of familial and sporadic multiple sclerosis. Mult. Scler. 2004, 10:266-271.
37. Zwemmer J.N., et al. No major association of ApoE genotype with disease characteristics and MRI findings in multiple sclerosis. Mult. Scler. 2004, 10:272-277.